Icecure medical ltd ICCM.US 總覽分析
ICCM 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分優異，但股利評分未超過2分，若公司開始配息，可能會有更優異的投資結果
ICCM 近期報酬表現
6.87%
Icecure medical ltd
2.24%
同產業平均
0.72%
S&P500
與 ICCM 同產業的標的表現
- MDAI Spectral ai inc價值 -趨勢 3 分波段 2 分籌碼 1 分股利 1 分查看更多
ICCM 公司資訊
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.